603259 药明康德
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入28,897,47938.93%45,456,16639,241,43140,340,80739,354,778
减:营业总成本16,254,49215.98%29,148,15527,342,26828,708,59129,800,811
    其中:营业成本13,319,00015.27%23,801,43522,964,51523,728,80024,677,217
               财务费用213,2583.42%398,191(786,684)(338,119)(247,968)
               资产减值损失(68,369)-78.73%(541,556)(1,236,258)(156,509)(175,951)
公允价值变动收益684,234-475.58%(137,098)186,958(37,809)770,079
投资收益227,724-93.79%8,588,017604,162233,849187,949
    其中:对联营企业和合营企业的投资收益147,430-38.64%452,582245,065(67,560)(46,271)
营业利润13,530,32836.24%23,930,08411,580,17511,872,28610,652,249
利润总额13,517,55936.44%23,906,15111,539,81211,831,99110,618,476
减:所得税费用2,391,22591.75%4,573,0851,972,0722,131,7311,715,866
净利润11,126,33428.47%19,333,0669,567,7409,700,2608,902,611
减:非控股权益46,160-53.59%182,483117,43193,51188,898
股东净利润11,080,17429.43%19,150,5829,450,3089,606,7498,813,713

市场价值指针
每股收益 (元) *3.80026.25%6.7003.2803.2703.010
每股派息 (元) *0.510-27.14%2.2790.9820.9900.893
每股净资产 (元) *27.92933.89%26.71520.30218.57015.737
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容